Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
James Irving Insider Profile
4 Followers
James Irving, Director at Abattis Bioceuticals, holds 1.34M shares in Abattis Bioceuticals (Ticker: ATTBF). Most recently, James Irving Sold $236,000 shares of Abattis Bioceuticals on Aug 04, 2018 for an estimated value of 35.40K.
Profitable Transactions
7 out of 10 Profitable Transactions
Average Return
+19.20%
Average return per transaction
Time Frame
Compare to
Insider Roles
Director
Roles that James Irving holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Buy
Date:May 09, 2016 - May 09, 2017
Return:+168.20%
The most profitable trade made by James Irving
James Irving's Trading History
List of latest transactions for each holding click on a transaction to see James Irving's performance on stock
You May Also Like
James Irving insider profile FAQ
What is the percentage of profitable transactions made by James Irving?
The percentage of profitable transactions made by James Irving is 70%.
What is the average return per transaction made by James Irving?
The average return per transaction made by James Irving is 19.20%.
What stocks does James Irving hold?
James Irving holds: ATTBF stocks.
What was James Irving’s latest transaction?
James Irving latest transaction was an Informative Sell of $35.40K.
What was James Irving's most profitable transaction?
James Irving’s most profitable transaction was an Informative Buy of ATTBF stock on May 9, 2016. The return on the trade was 168.20%.
What is James Irving's role in Abattis Bioceuticals?
James Irving's role in Abattis Bioceuticals is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.